Immunitybio Inc (IBRX)
Healthcare
Biotechnology
7.20 $
-3.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Immunitybio Inc (IBRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -305 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.4 | -25 | -39 | -49 | -63 | -152 | -172 | -274 | -338 | -367 | -391 | -305 | |
| 0.1 | 1.5 | 3.6 | 5.6 | 9.6 | 14 | 13 | 14 | 35 | 19 | 18 | 16 | |
| 0.8 | 211 | 74 | 37 | 2.0 | 3.4 | 2.2 | 57 | 40 | 49 | 34 | 37 | |
| – | – | – | – | 15 | -0.7 | 13 | 58 | 29 | – | – | – | |
| 61 | 0.3 | 3.8 | 3.2 | -0.6 | -16 | 16 | -15 | -16 | 4.0 | -19 | -54 | |
| 0.3 | 2.2 | 6.6 | 35 | 13 | 4.3 | 1.7 | 34 | 78 | 31 | 6.9 | 3.8 | |
| -0.3 | -175 | -114 | 100 | 57 | 19 | -20 | -85 | 27 | -30 | -12 | -150 | |
| – | – | – | – | – | 2.3 | 4.4 | 334 | 0.6 | – | – | – | |
| – | -4.8 | -16 | -15 | -0.2 | -2.5 | -0.5 | -4.1 | -0.6 | -3.4 | – | – | |
| – | – | – | – | 36 | 48 | 64 | 339 | 174 | 259 | -0.1 | 2.9 | |
| 64 | 317 | -16 | -35 | -0.8 | 114 | 151 | 505 | 234 | 558 | 282 | 400 | |
| 59 | 117 | -168 | 16 | -7.1 | -19 | -41 | 146 | -76 | 161 | -122 | -54 | |
| -5.7 | -28 | -45 | -84 | -76 | -156 | -173 | -308 | -416 | -397 | -398 | -309 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.